Literature DB >> 24613457

Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity.

Jun Cai1, Bowen Song1, Yunxin Cai1, Yu Ma1, Ai-Leen Lam2, Julia Magiera2, Sunder Sekar2, Bruce D Wyse2, Akihiro Ambo3, Yusuke Sasaki3, Lawrence H Lazarus4, Maree T Smith5, Tingyou Li6.   

Abstract

Analogues of endomorphin (Dmt-Pro-Xaa-Xaa-NH2) modified at position 4 or at positions 4 and 3, and tripeptides (Dmt-Pro-Xaa-NH2) modified at position 3, with various phenylalanine analogues (Xaa=Trp, 1-Nal, 2-Nal, Tmp, Dmp, Dmt) were synthesized and their effects on in vitro opioid activity were investigated. Most of the peptides exhibited high μ-opioid (MOP) receptor binding affinity (KiMOP=0.13-0.81nM), modest MOP-selectivity (Kiδ-opioid (DOP)/KiMOP=3.5-316), and potent functional MOP agonism (GPI, IC50=0.274-249nM) without DOP and κ-opioid (KOP) receptor agonism. Among them, compounds 7 (Dmt-Pro-Tmp-Tmp-NH2) and 9 (Dmt-Pro-1-Nal-NH2) were opioids with potent mixed MOP receptor agonism/DOP receptor antagonism and devoid of β-arrestin2 recruitment activity. They may offer a unique template for the discovery of potent analgesics that produce less respiratory depression, less gastrointestinal dysfunction and that have a lower propensity to induce tolerance and dependence compared with morphine.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Analgesics; Dmt; Endomorphin-2; Opioid

Mesh:

Substances:

Year:  2014        PMID: 24613457     DOI: 10.1016/j.bmc.2014.02.015

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome.

Authors:  Marta Zielińska; Agata Jarmuż; Andrzej Wasilewski; Gerta Cami-Kobeci; Stephen Husbands; Jakub Fichna
Journal:  Pharmacol Rep       Date:  2016-12-05       Impact factor: 3.024

2.  In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.

Authors:  Jessica P Anand; Kelsey E Kochan; Anthony F Nastase; Deanna Montgomery; Nicholas W Griggs; John R Traynor; Henry I Mosberg; Emily M Jutkiewicz
Journal:  Br J Pharmacol       Date:  2018-04-24       Impact factor: 8.739

3.  Rapid Synthesis of Boc-2',6'-dimethyl-l-tyrosine and Derivatives and Incorporation into Opioid Peptidomimetics.

Authors:  Aaron M Bender; Nicholas W Griggs; Chao Gao; Tyler J Trask; John R Traynor; Henry I Mosberg
Journal:  ACS Med Chem Lett       Date:  2015-10-19       Impact factor: 4.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.